Aurora Cannabis Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
4.8
Bearish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
ACB
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-23% margin).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $6.42 (+84.5%)
1 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
ACB
MRK
—
Trailing P/E
31.5×
-31.6×
Forward P/E
11.5×
-22.5%
Profit Margin
13.6%
36.0%
Gross Margin
76.6%
-15.5%
ROE
—
6.8%
Revenue Growth
4.9%
-94.7%
Earnings Growth
—
1.32
Beta
0.28
—
Price / Book
—
$206M
Market Cap
$277.0B
$3 – $7
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →